文献速递真菌感染细菌感染、耐药与抗菌药物

每周两次米卡芬净用于急性淋巴细胞白血病患儿侵袭性真菌病预防的药代动力学评估:一项前瞻性观察性队列研究

Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

该前瞻性观察性队列研究纳入61例接受白血病诱导治疗的患儿,给予每周两次米卡芬净9 mg/kg(最大300 mg)并至少进行一次药代动力学评估,采用非线性混合效应模型分析。结果显示,5、7、9 mg/kg及按体重带固定剂量方案的模拟暴露(AUC0-168 h)均超过成人每日一次100 mg的参考暴露,提示每周两次方案可为念珠菌治疗提供足够暴露。

要点

  • 每周两次米卡芬净9 mg/kg(最大300 mg)方案在儿童白血病患者中模拟暴露超过成人参考暴露。
  • 5、7、9 mg/kg及按体重带固定剂量方案的AUC0-168 h均高于成人每日一次100 mg的参考暴露。
  • 患儿米卡芬净清除率低于成人(P < 0.01),可能解释暴露量较高。

核心结论

  • 所有每周两次方案似乎均可为念珠菌治疗提供足够暴露,模拟暴露远高于成人参考暴露。
  • 这些发现为每周两次与每日一次米卡芬净方案药代动力学等效提供了依据。
  • 患儿米卡芬净暴露较高似乎源于清除率低于预期。
  • 在没有目标浓度假设和同类药物疗效相同的前提下,结果不能推广至曲霉预防。

研究设计与样本

  • 前瞻性观察性队列研究,纳入61例接受白血病诱导治疗的患儿,给予每周两次米卡芬净9 mg/kg(最大300 mg)并至少进行一次药代动力学评估。
  • 采用非线性混合效应模型分析,模型构建时用现有成人数据强化儿科数据。
  • 对5、7、9 mg/kg及按体重带固定剂量的每周两次方案进行蒙特卡洛模拟,并与成人每日一次100 mg方案的暴露进行比较。

主要发现

  • 患儿中位年龄4.0岁(范围1.0-17),中位体重19.5 kg(范围8.60-182)。
  • 二室模型最佳拟合数据。
  • 患儿清除率和中央分布容积低于成人(P < 0.01)。
  • 5、7、9 mg/kg及按体重带固定剂量方案的预测暴露(AUC0-168 h)均超过成人参考暴露。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 在没有目标浓度假设和同类药物疗效相同的前提下,结果不能推广至曲霉预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the pharmacokinetics of twice-a-week micafungin prophylaxis in paediatric leukaemic patients to provide the rationale for this approach. METHODS: Twice-a-week micafungin at a dose of 9 mg/kg (maximum 300 mg) was given during the leukaemic induction treatment with at least one pharmacokinetic assessment. Non-linear mixed-effects modelling was used for analysis. For model building, our paediatric data were strengthened with existing adult data. Monte Carlo simulations were performed with twice-a-week dosing regimens of 5, 7 and 9 mg/kg and flat dosing per weight band. Simulated paediatric exposures were compared with the exposure in adults after a once-daily 100 mg regimen. RESULTS: Sixty-one paediatric patients were included with a median age and weight of 4.0 years (range 1.0-17) and 19.5 kg (range 8.60-182), respectively. A two-compartment model best fitted the data. CL and central Vd were lower (P < 0.01) in paediatric patients compared with adults. Predicted exposures (AUC0-168 h) for the 5, 7 and 9 mg/kg and flat dosing per weight band regimens exceeded the adult reference exposure. CONCLUSIONS: All twice-a-week regimens appeared to result in adequate exposure for Candida therapy, with simulated exposures well above the adult reference exposure. These findings provide the rationale for the pharmacokinetic equivalence of twice-a-week and once-daily micafungin regimens. The greater micafungin exposures seem to be caused by a slower-than-anticipated CL in our paediatric leukaemic patients. The generalizability of our results for Aspergillus prophylaxis cannot be provided without assumptions on target concentrations and within-class identical efficacy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Bury D, Wolfs TFW, Ter Heine R, et al. Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study. J Antimicrob Chemother. 2022. PMID: 34939125. doi:10.1093/jac/dkab467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。